These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22641164)

  • 1. Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
    Karan D; Holzbeierlein JM; Van Veldhuizen P; Thrasher JB
    Nat Rev Urol; 2012 May; 9(7):376-85. PubMed ID: 22641164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
    Gardner TA; Elzey BD; Hahn NM
    Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-based therapies for metastatic prostate cancer: an update.
    Hossain MK; Nahar K; Donkor O; Apostolopoulos V
    Immunotherapy; 2018 Feb; 10(4):283-298. PubMed ID: 29421982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of immunological approaches for the treatment of prostate cancer.
    Drake CG; Antonarakis ES
    Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in immunotherapy for the treatment of prostate cancer.
    Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
    Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of immunological therapies for prostate cancer.
    Antonarakis ES; Drake CG
    Curr Opin Urol; 2010 May; 20(3):241-6. PubMed ID: 20179598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Therapy for Prostate Cancer.
    Yeku O; Slovin SF
    Cancer J; 2016; 22(5):334-341. PubMed ID: 27749327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic approaches in prostate cancer: combinations and clinical integration.
    Slovin SF
    Am Soc Clin Oncol Educ Book; 2015; ():e275-83. PubMed ID: 25993186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of immunotherapy into the management of advanced prostate cancer.
    Kantoff P; Higano CS
    Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current role of immunotherapy for the treatment of prostate cancer.
    Porfyris O; Kalomoiris P
    J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy for metastatic prostate cancer: do we really need this?].
    Heidenreich A
    Urologe A; 2012 Jan; 51(1):32-8. PubMed ID: 22258374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.